PMID- 24980277
OWN - NLM
STAT- MEDLINE
DCOM- 20150818
LR  - 20220311
IS  - 1365-2133 (Electronic)
IS  - 0007-0963 (Print)
IS  - 0007-0963 (Linking)
VI  - 171
IP  - 6
DP  - 2014 Dec
TI  - Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the 
      treatment of scalp psoriasis in adolescents 12-17 years of age.
PG  - 1470-7
LID - 10.1111/bjd.13235 [doi]
AB  - BACKGROUND: Plaque psoriasis has a relatively high prevalence in adolescence, 
      resulting in a significant impact on quality of life, including social 
      interactions. OBJECTIVES: The primary objective was to assess the safety of 
      once-daily application of fixed-combination calcipotriol plus betamethasone 
      dipropionate gel in adolescent scalp psoriasis. Assessment of efficacy was a 
      secondary objective. METHODS: This phase II, multicentre, single-arm, open-label, 
      8-week trial included patients aged 12-17 years with moderate-to-very severe 
      scalp psoriasis according to Investigator's Global Assessment (IGA) (>/= 10% of the 
      scalp area affected). RESULTS: Seventy-eight patients received treatment. 
      Twenty-seven patients (35%) reported a total of 64 adverse events (AEs); most 
      were mild (33/64) or moderate (22/64) in severity and there were no serious AEs. 
      No cases of hypercalcaemia were reported, and the mean changes from baseline to 
      end of treatment in albumin-corrected serum calcium (0.00 mmol L(-1)), 24-h 
      urinary calcium excretion (-0.03 mmol per 24 h) and urinary calcium-to-creatinine 
      ratio (-0.12 mmol g(-1)) were not considered clinically relevant. At the end of 
      treatment 66 patients (85%) were clear or almost clear according to IGA. There 
      was an 80% improvement in mean Total Sign Score from baseline to end of 
      treatment. In total, at the end of treatment, 87% of patients rated their scalp 
      psoriasis as clear or very mild, and 75 (96%) had no or mild pruritus compared 
      with 14 (18%) at baseline. CONCLUSIONS: Once-daily calcipotriol plus 
      betamethasone dipropionate gel is well tolerated and efficacious for scalp 
      psoriasis in adolescents.
CI  - (c) 2014 The Authors. British Journal of Dermatology published by John Wiley & Sons 
      Ltd on behalf of British Association of Dermatologists.
FAU - Gooderham, M
AU  - Gooderham M
AD  - SKiN Centre for Dermatology, 743 Lansdowne Street West, Peterborough, ON, Canada, 
      K9J 1Z.
FAU - Debarre, J-M
AU  - Debarre JM
FAU - Keddy-Grant, J
AU  - Keddy-Grant J
FAU - Xu, Z
AU  - Xu Z
FAU - Kurvits, M
AU  - Kurvits M
FAU - Goodfield, M
AU  - Goodfield M
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20141022
PL  - England
TA  - Br J Dermatol
JT  - The British journal of dermatology
JID - 0004041
RN  - 0 (Dermatologic Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Gels)
RN  - 143NQ3779B (calcipotriene)
RN  - 826Y60901U (betamethasone-17,21-dipropionate)
RN  - 9842X06Q6M (Betamethasone)
RN  - FXC9231JVH (Calcitriol)
SB  - IM
MH  - Administration, Cutaneous
MH  - Adolescent
MH  - Betamethasone/administration & dosage/adverse effects/*analogs & derivatives
MH  - Calcitriol/administration & dosage/adverse effects/*analogs & derivatives
MH  - Child
MH  - Dermatologic Agents/administration & dosage/*adverse effects
MH  - Drug Administration Schedule
MH  - Drug Combinations
MH  - Female
MH  - Gels
MH  - Humans
MH  - Male
MH  - Psoriasis/*drug therapy
MH  - Scalp Dermatoses/*drug therapy
MH  - Treatment Outcome
PMC - PMC4298245
EDAT- 2014/07/02 06:00
MHDA- 2015/08/19 06:00
CRDT- 2014/07/02 06:00
PHST- 2014/06/16 00:00 [accepted]
PHST- 2014/07/02 06:00 [entrez]
PHST- 2014/07/02 06:00 [pubmed]
PHST- 2015/08/19 06:00 [medline]
AID - 10.1111/bjd.13235 [doi]
PST - ppublish
SO  - Br J Dermatol. 2014 Dec;171(6):1470-7. doi: 10.1111/bjd.13235. Epub 2014 Oct 22.